简介Hepatic artery infusion chemotherapy (HAIC) is a treatment modality for advanced hepatocellular carcinoma (HCC).
肝动脉输注化疗(HAIC)是治疗晚期肝癌(HCC)的一种治疗方式。
HAIC entails infusing chemotherapeutic agents directly into hepatic tumors through the percutaneous catheterization of feeding arteries.
HAIC需要通过经皮供血动脉将化疗药物直接注入肝肿瘤。
Because HCC tumors are primarily supplied by the hepatic arteries, HAIC provides a higher intratumoral concentration of chemotherapeutic agents and avoids the first-pass effect, theoretically yielding greater treatment efficacy and less hepatocellular injury [1].
These chemotherapeutic agents subsequently went through the body by circulation and also offered systemic anti-tumor effect but with less concentration advantage.
这些化疗药物随后通过循环进入体内，也具有全身抗肿瘤作用，但浓度优势较低。
Therefore, HAIC is basically a systemic treatment with more prominent locoregional efficacy.
因此，HAIC基本上是一种全身治疗，局部疗效更突出的方法。
These peculiar features make HAIC distinct from other transarterial therapeutic approaches for HCC, such as transarterial chemoembolization (TACE) and selective internal radiation therapy (SIRT), which yield locoregional efficacy only and failed to provide survival benefit for patients with advanced HCC [2,3,4].
这些特殊的特征使HAIC不同于其他经动脉HCC治疗方法，如经动脉化疗栓塞(TACE)和选择性内放疗(SIRT)，后者仅产生局部疗效，不能为晚期HCC[2,3,4]患者提供生存效益。
Furthermore, TACE is considered as relative contraindicated in patients with portal vein thrombosis (PVT), since reduced blood supply in both portal vein system and hepatic arteries may cause substantial hepatocyte injury, especially for Vp3/4 thrombosis (Figure 1).
此外，TACE被认为是门静脉血栓形成(PVT)患者的相对禁忌症，因为门静脉系统和肝动脉的血供减少可能导致大量的肝细胞损伤，特别是Vp3/4血栓形成（图1）。
|
